Mutations in TMSB4X may enhance the migration and invasion potential of tumor cells.[16] IRF4, a key transcription factor in B-cell differentiation, immune regulation, and metabolism, has mutations closely associated with poor lymphoma prognosis.[17] This combination of genomic instability and multiple gene mutations likely contributed to the patient’s rapidly progressing disease. Here, TMSB4X is linked to neoplasm.